Drug profile · INN
infliximab
INFLECTRA
infliximab (INFLECTRA) is a tnf-alpha inhibitor. Associated with Pfizer Australia Pty Ltd. Current US regulatory status: approved.
Drug details — infliximab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 63
- Data quality
- 0.83
Quick answer
infliximab (INFLECTRA) is a tnf-alpha inhibitor. Associated with Pfizer Australia Pty Ltd. Current US regulatory status: approved.
Key facts
Mechanism of action
TNF-alpha inhibitor
Primary target: Tumor necrosis factor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is infliximab?
infliximab (INFLECTRA) is a tnf-alpha inhibitor. Associated with Pfizer Australia Pty Ltd. Current US regulatory status: approved.
What is the brand name for infliximab?
INFLECTRA is a marketed brand name for infliximab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of infliximab?
infliximab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.